Global Duchenne Muscular Dystrophy (DMD) Treatment Market Report and Forecast 2024-2032

Global Duchenne Muscular Dystrophy (DMD) Treatment Market Outlook

The global market for Duchenne muscular dystrophy (DMD) treatment reached a value of about USD 1.46 million in 2023. The industry is further expected to grow at a CAGR of approximately 12.50% in the forecast period of 2024-2032 to reach a value of around USD 4.22 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America and Europe to be Significant Regional Markets for Duchenne Muscular Dystrophy (DMD) Treatment

North America and Europe are currently the two largest markets in the global Duchenne muscular dystrophy (DMD) treatment market as these are expected to account for a large proportion of the market in the forecast period. New product innovations, rising incidence of Duchenne muscular dystrophy, rise in the demand for early diagnosis, high healthcare expenditure, increasing investments in research and development of new treatment options, and government awareness programs are the major factors anticipated to propel the market growth in these regions. The United States is the dominant country in North America and is projected to maintain its lead due to rising disease incidence and the anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe.

Exon Skipping Segment Expected to Dominate the Market Growth

The increasing adoption of EXONDYS 51 has driven the segment growth. EXONDYS 51 refers to the first FDA-approved Duchenne muscular dystrophy treatment for patients who suffer from a confirmed genetic mutation in the dystrophin gene, which can be treated by skipping exon 51. It helps the body make a shorter form of the dystrophin protein in some patients. The internal deletions mainly cause Duchenne muscular dystrophy in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic methods is to mask an exon close to the site where the others are missing so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.

Also, the market players are increasingly focusing on frequent launches in exon-skipping technology, which is a significant factor driving the segment and propelling the growth of the Duchenne muscular dystrophy (DMD) treatment market. For instance, In December 2019, Sarepta’s exon-skipping drug, VYONDYS 53 (golodirsen), was approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.

Market Segmentations

Duchenne muscular dystrophy (DMD) is a hereditary condition that causes muscle weakening and deterioration. DMD is caused by a mutation in the gene that codes for the dystrophin protein, which is found in muscles. It is a rare muscular condition that usually affects men. Intellectual incapacity, muscle weakness, and walking and breathing difficulties are among the common symptoms.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on therapeutic approaches, the market is segmented into:

• Molecular-based Therapies
  • Mutation Suppression
  • Exon Skipping
• Steroid Therapy
• Other Therapeutic Approaches

The several distribution channels of the market are:

• Hospitals 
• Retail and Online Pharmacies

The end-users of the market are:

• Hospitals
• Home Care Settings
• Clinics

The regional markets for the Duchenne muscular dystrophy (DMD) treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

\

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Introduction of Novel Drugs and Therapies Augmenting the Market Growth

The major drivers in the global Duchenne muscular dystrophy (DMD) treatment market include the introduction of novel drugs and therapies, significant support from various firms for drug research, disease-modifying therapies, and support from patient advocacy groups on the regulatory approval process. An increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy and a broad product pipeline are likely to drive the global market growth during the forecast period. Mutation-specific therapies are expected to emerge as a breakthrough in the treatment of Duchenne muscular dystrophy. The increasing disease burden of Duchenne muscular dystrophy, increased investments in biopharmaceutical research and development to release novel disease therapeutics, and increased DMD awareness campaigns also contribute to the market's growth. Various organisations are involved in spreading awareness and investing in research and development to find an effective treatment for this disease, contributing to the global market growth. Other factors, such as constant research on gene therapy, stem cell therapy, and exon skipping drugs for the treatment of DMD, are expected to propel the market growth of DMD treatment. Additionally, favourable reimbursement policies and government initiatives supporting target-specific therapies are anticipated to fuel the market during the forecasted period.

Key Players in the Market for Global Duchenne Muscular Dystrophy (DMD) Treatment

The report gives a detailed analysis of the following key players in the global Duchenne muscular dystrophy (DMD) treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.
• Sarepta Therapeutics, Inc.
• PTC Therapeutics Inc.
• FibroGen, Inc
• F. Hoffmann-La Roche Ltd
• NS Pharma, Inc.
• Solid Biosciences Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report